Medgend Icon

Ledgend of Medicine







discontinued


Mellitus

What is diabetes?

Diabetes, also known as diabetes mellitus, is a disease in which your blood glucose, or blood sugar, levels are too high. Glucose is your body's main source of energy. Your body can make glucose, but it also comes from the food you eat. Insulin is a hormone made by your pancreas. Insulin helps move glucose from your bloodstream into your cells, where it can be used for energy.

If you have diabetes, your body can't make insulin, can't use insulin as well as it should, or both. Too much glucose stays in your blood and doesn't reach your cells. This can cause glucose levels to get too high. Over time, high blood glucose levels can lead to serious health conditions. But you can take steps to manage your diabetes and try to prevent these health problems.

What are the types of diabetes?

There are different types of diabetes:

  • Type 1 diabetes. If you have type 1 diabetes, your body makes little or no insulin. It happens when your immune system attacks and destroys the cells that produce insulin.
  • Type 2 diabetes. This is the most common form of diabetes. If you have type 2 diabetes, your body may still be able to make insulin, but your cells don't respond well to insulin. They can't easily take up enough glucose from your blood.
  • Gestational diabetes. This is a form of diabetes that develops during pregnancy. It happens when your body can't make the extra insulin it needs during pregnancy.
What causes diabetes?

The different types of diabetes have different causes:

  • Researchers think type 1 diabetes is caused by genes and factors in the environment that might trigger the disease.
  • Type 2 diabetes is caused by several factors, including lifestyle factors and genes. The lifestyle factors include not being physically active and being overweight or having obesity.
  • Researchers think gestational diabetes is caused by the hormonal changes of pregnancy along with genetic and lifestyle factors.
Who is more likely to develop diabetes?

The different types of diabetes have different risk factors:

  • You can develop type 1 diabetes at any age, but it most often starts in childhood. Having a parent or sibling with type 1 diabetes may increase your chance of developing it.
  • You are at higher risk of developing type 2 diabetes if you:
    • Are overweight or have obesity.
    • Are over age 35. Children, teenagers, and younger adults can get diabetes, but it is more common in middle-aged and older adults.
    • Have a family history of diabetes.
    • Have prediabetes. This means that your blood glucose is higher than normal, but it's not high enough to be called diabetes.
    • Had gestational diabetes.
    • Have given birth to a baby weighing 9 pounds or more.
    • Are African American, American Indian, Asian American, Hispanic/Latino, or Pacific Islander.
    • Are not physically active.
    • Have certain other health conditions, such as high blood pressure or polycystic ovary syndrome (PCOS).
  • You are at higher risk of developing gestational diabetes if you:
    • Are overweight or have obesity.
    • Have a family history of diabetes.
    • Had gestational diabetes in a previous pregnancy.
    • Have given birth to a baby weighing 9 pounds or more.
    • Have polycystic ovary syndrome (PCOS).
    • Are African American, Hispanic/Latino, American Indian, Alaska Native, Native Hawaiian, or Pacific Islander.
What are the symptoms of diabetes?

The symptoms of diabetes may include:

  • Feeling very thirsty
  • Feeling very hungry
  • Urinating (peeing) more often, including at night
  • Fatigue
  • Blurry vision
  • Numbness or tingling in the feet or hands
  • Sores that do not heal
  • Losing weight without trying

But it's important to know that your symptoms may vary, depending on which type you have:

  • The symptoms of type 1 diabetes usually come on quickly and can be severe.
  • With type 2 diabetes, the symptoms often develop slowly, over several years. The symptoms can be so mild that you might not even notice them.
  • Gestational diabetes often has no symptoms. If you do have symptoms, they may be mild. If you are pregnant, you will usually be screened for this condition between 24 and 28 weeks of pregnancy.
How is diabetes diagnosed?

To find out if you have diabetes, your health care provider will use one or more glucose blood tests. There are several types, including the A1C test.

What are the treatments for diabetes?

Treatment for diabetes involves managing your blood glucose levels:

  • If you have type 1 diabetes, you will need to take daily doses of insulin, either by injection or through a special pump. Some people also need to take another type of diabetes medicine that works with insulin.
  • If you have type 2 diabetes, you may be able to manage or even reverse it by making lifestyle changes. These include eating a healthy diet, staying at healthy weight, and getting regular physical activity. Some people also need to take diabetes medicines to manage their diabetes.
  • If you have gestational diabetes, you may be able to lower your glucose levels by eating a healthy diet and getting regular exercise. But be sure to talk to your provider about your treatment options. Gestational diabetes usually goes away after you give birth. But you will have a higher risk of developing type 2 diabetes later.

Checking your blood glucose levels is also an important part of managing your diabetes. Ask your provider about the best way to check your blood glucose level and how often you should check it.

Can diabetes be prevented?

Type 1 diabetes can't be prevented.

You may be able to delay or prevent type 2 diabetes through the same lifestyle changes that are used to manage diabetes (eating a healthy diet, staying at a healthy weight, and getting regular physical activity). These lifestyle changes may also help prevent gestational diabetes.

NIH: National Institute of Diabetes and Digestive and Kidney Diseases

Mellitus FDA Approved Drugs

ACTOPLUS MET XR [Metformin HydrochlorideC4H11N5ClH : Pioglitazone HydrochlorideC19H20N2O3SClH]
RX
-
1gm : eq 15mg base (oral tablet, extended release)
1gm : eq 30mg base (oral tablet, extended release)
Takeda Pharms UsaMay 12, 2009
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with pioglitazone and metformin or who have inadequate glycemic control on pioglitazone or metformin alone.
  • Adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes who are already treated with a pioglitazone and metformin.
  • To reduce gastrointestinal side effects administer with a meal; as starting dose administer once daily with evening meal.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ADLYXIN [Lixisenatide]
RX
-
0.15mg/3ml (0.05mg/ml) (subcutaneous solution)
0.3mg/3ml (0.1mg/ml) (subcutaneous solution)
Sanofi-aventis UsJul 27, 2016
  • Combination treatment with a glitazone for improvement of glycemic control in type 2 diabetes mellitus patients.
  • Improvement in glycemic control in type 2 diabetes mellitus patients by use of a pen injector.
efficacy
4.0  (1)
side effects
0.0  (0)
danger
0.0  (0)

UNK

AFREZZA [Insulin Recombinant Human]
RX
-
12 units/inh (inhalation powder)
4 units/inh (inhalation powder)
8 units/inh (inhalation powder)
MannkindApr 17, 2015
  • Administration of a composition comprising insulin complexed with a diketopiperazine..
  • Administration of a composition comprising insulin complexed with microparticles of a diketopiperazine..
  • Administration of fdkp microparticles comprising insulin..
  • Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder..
  • Method of controlling glycemia in diabetics by administering an initial dose of insulin-fdkp with a meal; determining blood glucose level 1-2 hrs after and administering a supplemental dose of insulin-fdkp if postprandial glucose level is >140 mg/dl.
  • Method of delivering to a patient with diabetes mellitus in a single inhalation, greater than 75% of a dry powder dose comprising insulin and fumaryl diketopiperazine using a high resistance to flow dry powder inhaler..
  • Pulmonary administration of a compisition comprising insulin bound to a diketopiperazine..
  • Pulmonary administration of a composition comprising insulin bound to a complexing agent..
  • Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin..
  • Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin..
  • Treatment of diabetes mellitus with an inhaled insulin to improve glycemic control using a dry powder inhalation system comprising an inhaler, a cartridge and a dry powder medicament comprising insulin in a single inhalation.
  • Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin.
  • Use of an inhaler to administer dry powder medicament.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

APIDRA [Insulin Glulisine Recombinant]
RX
-
1000 units/10ml (100 units/ml) (iv (infusion), subcutaneous injectable)
300 units/3ml (100 units/ml) (iv (infusion), subcutaneous injectable)
Sanofi Aventis UsApr 16, 2004
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
  • Method of treating a patient suffering from diabetes mellitus.
efficacy
1.0  (1)
side effects
0.0  (0)
danger
0.0  (0)

UNK

APIDRA SOLOSTAR [Insulin Glulisine Recombinant]
RX
-
300 units/3ml (subcutaneous injectable)
Sanofi Aventis UsFeb 24, 2009
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
  • Method of treating a patient suffering from diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYDUREON [Exenatide Synthetic]
RX
-
2mg/vial (subcutaneous for suspension, extended release)
Astrazeneca AbJan 27, 2012
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Reductions in body weight are observed with exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Treatment of type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYDUREON PEN [Exenatide Synthetic]
RX
-
2mg (subcutaneous for suspension, extended release)
Astrazeneca AbFeb 28, 2014
  • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Method for treating type 2 diabetes using a sustained-release composition containing exenatide.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Reductions in body weight are observed with exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Treatment of type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

BYETTA [Exenatide Synthetic]
RX
-
300mcg/1.2ml (250mcg/ml) (subcutaneous injectable)
600mcg/2.4ml (250mcg/ml) (subcutaneous injectable)
Astrazeneca AbApr 28, 2005
  • Lowering plasma glucagon in a subject in need thereof, including one with type 2 diabetes, by administering an exendin or analog, such as exendin-4.
  • Reducing food intake in a subject with type 2 diabetes by administering an exendin, such as exendin-4.
  • Reducing gastric motility or delaying gastric emptying by administering an exendin, such as exendin-4.
  • Stimulating insulin release by administering exenatide.
  • Treating type 2 diabetes mellitus with exenatide by stimulating insulin release.
  • Use of exenatide may result in reduction in appetite..
  • Use of exenatide may result in reduction in body weight.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

FARXIGA [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O]
RX
-
eq 10mg base (oral tablet)
eq 5mg base (oral tablet)
Astrazeneca AbJan 8, 2014
  • Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

GLYXAMBI [EmpagliflozinC23H27ClO7 : LinagliptinC25H28N8O2]
RX
-
10mg : 5mg (oral tablet)
25mg : 5mg (oral tablet)
Boehringer IngelheimJan 30, 2015
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without insulin or a sulfonylurea).
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin (with or without metformin).
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin and metformin.
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

INVOKAMET [Canagliflozin2C24H25FO5SH2O : Metformin HydrochlorideC4H11N5ClH]
RX
-
150mg : 1gm (oral tablet)
150mg : 500mg (oral tablet)
Janssen PharmsAug 8, 2014
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

INVOKAMET XR [Canagliflozin2C24H25FO5SH2O : Metformin HydrochlorideC4H11N5ClH]
RX
-
150mg : 1gm (oral tablet, extended release)
150mg : 500mg (oral tablet, extended release)
Janssen PharmsSep 20, 2016
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

INVOKANA [Canagliflozin2C24H25FO5SH2O]
RX
-
100mg (oral tablet)
300mg (oral tablet)
Janssen PharmsMar 29, 2013
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JANUMET [Metformin HydrochlorideC4H11N5ClH : Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
1gm : eq 50mg base (oral tablet)
500mg : eq 50mg base (oral tablet)
Merck Sharp DohmeMar 30, 2007
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JANUMET XR [Metformin HydrochlorideC4H11N5ClH : Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
1gm : eq 100mg base (oral tablet, extended release)
1gm : eq 50mg base (oral tablet, extended release)
500mg : eq 50mg base (oral tablet, extended release)
Merck Sharp DohmeFeb 2, 2012
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended release is appropriate.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JANUVIA [Sitagliptin PhosphateC16H15F6N5OH2OH3O4P]
RX
-
eq 100mg base (oral tablet)
eq 25mg base (oral tablet)
eq 50mg base (oral tablet)
Merck Sharp DohmeOct 16, 2006
  • Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin and/or a ppar-gamma agonist and/or sulfonylurea and/or insulin.
  • Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin..
  • Improvement of glycemic control in adults with type 2 diabetes mellitus.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with insulin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin and a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with a ppar-gamma agonist.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JARDIANCE [EmpagliflozinC23H27ClO7]
RX
-
10mg (oral tablet)
25mg (oral tablet)
Boehringer IngelheimAug 1, 2014
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with empagliflozin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JENTADUETO [LinagliptinC25H28N8O2 : Metformin HydrochlorideC4H11N5ClH]
RX
-
2.5mg : 1gm (oral tablet)
2.5mg : 500mg (oral tablet)
2.5mg : 850mg (oral tablet)
Boehringer IngelheimJan 30, 2012
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

JENTADUETO XR [LinagliptinC25H28N8O2 : Metformin HydrochlorideC4H11N5ClH]
RX
-
2.5mg : 1gm (oral tablet, extended release)
Boehringer IngelheimMay 27, 2016
  • Method of treating type 2 diabetes in patients who have not been previously treated with an antihyperglycemic agent by administering linagliptin in combination with metformin.
  • Method of treating type 2 diabetes in patients with insufficient glycemic control despite therapy with one or more conventional antihyperglycemic agents by administering linagliptin in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and, optionally, a sulfonylurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
  • Method of treating type 2 diabetes.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

KOMBIGLYZE XR [Metformin HydrochlorideC4H11N5ClH : Saxagliptin HydrochlorideC18H25N3O2ClH]
RX
-
1gm : eq 2.5mg base (oral tablet, extended release)
1gm : eq 5mg base (oral tablet, extended release)
500mg : eq 5mg base (oral tablet, extended release)
Astrazeneca AbNov 5, 2010
  • Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both saxagliptin and metformin is appropriate.
  • Method for treating type ii diabetes mellitus by administering saxagliptin in combination with metformin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LANTUS [Insulin Glargine Recombinant]
RX
-
100 units/ml (injection injectable)
Sanofi Aventis UsApr 20, 2000
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LANTUS SOLOSTAR [Insulin Glargine Recombinant]
RX
-
300 units/3ml (100 units/ml) (injection injectable)
Sanofi Aventis UsApr 27, 2007
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LEVEMIR [Insulin Detemir Recombinant]
RX
-
1000 units/10ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncJun 16, 2005
  • Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

LEVEMIR FLEXTOUCH [Insulin Detemir Recombinant]
RX
-
300 units/3ml (100 units/ml) (subcutaneous injectable)
Novo Nordisk IncOct 31, 2013
  • Levemir is a long-acting basal insulin analog that is indicated in the treatment of patients with diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

ONGLYZA [Saxagliptin HydrochlorideC18H25N3O2ClH]
RX
-
eq 2.5mg base (oral tablet)
eq 5mg base (oral tablet)
Astrazeneca AbJul 31, 2009
  • Method for treating type ii diabetes by administering saxagliptin.
  • Method for treating type ii diabetes mellitus by administering saxagliptin alone or in combination with insulin, metformin, a thiazolidinedione, glyburide or metformin plus a sulfonylurea.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

QTERN [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O : Saxagliptin HydrochlorideC18H25N3O2ClH]
RX
-
eq 10mg base : eq 5mg base (oral tablet)
Astrazeneca AbFeb 27, 2017
  • Method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin.
  • Method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

SOLIQUA 100/33 [Insulin GlargineC267H404N72O78S6 : Lixisenatide]
RX
-
300 units/3ml : 99mcg/3ml (100 units/ml : 33mcg/ml) (subcutaneous solution)
Sanofi-aventis UsNov 21, 2016
  • Improvement in glycemic control in adults with type 2 diabetes mellitus inadequately controlled by basal insulin or lixisenatide by use of a pen injector with a threaded drive sleeve.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TOUJEO SOLOSTAR [Insulin Glargine Recombinant]
RX
-
300 units/ml (300 units/ml) (subcutaneous solution)
Sanofi Us ServicesFeb 25, 2015
  • Improvement in glycemic control in diabetes mellitus patients by use of a pen injector with a threaded drive sleeve.
  • Improvement in glycemic control in diabetes mellitus patients.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

TRADJENTA [LinagliptinC25H28N8O2]
RX
-
5mg (oral tablet)
Boehringer IngelheimMay 2, 2011
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with pioglitazone.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-4 inhibitor in combination with sulfonlyurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea.
  • Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidaste-iv inhibitor.
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with insulin (with or without metformin and/or pioglitazone).
  • Method of treating type 2 diabetes mellitus by administering linagliptin in combination with metformin.
  • Method of treating type 2 diabetes mellitus by administering linagliptin.
  • Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and for whom metformin therapy is inappropriate by administering linagliptin.
  • Method of treating type 2 diabetes mellitus in patients with severe chronic renal impairment and who are ineligible for metformin therapy by administering linagliptin.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

VICTOZA [Liraglutide Recombinant]
RX
-
18mg/3ml (6mg/ml) (subcutaneous solution)
Novo Nordisk IncJan 25, 2010
  • A method for improving glycemic control in adults with type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WELCHOL [Colesevelam Hydrochloride(C13H27N)n(C12H27ClN2)n(C9H18N2O)n(C3H7N)nClH]
RX
-
1.875gm/packet (oral for suspension)
3.75gm/packet (oral for suspension)
625mg (oral tablet)
Daiichi SankyoOct 2, 2009
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

XIGDUO XR [Dapagliflozin PropanediolC21H25ClO6C3H8O2H2O : Metformin HydrochlorideC4H11N5ClH]
RX
-
eq 10mg base : 1gm (oral tablet, extended release)
eq 10mg base : 500mg (oral tablet, extended release)
eq 5mg base : 1gm (oral tablet, extended release)
eq 5mg base : 500mg (oral tablet, extended release)
Astrazeneca AbOct 29, 2014
  • Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone.
  • Treatment of type 2 diabetes mellitus.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Felter's Materia Medica on Mellitus

AVENA SATIVA
   The unripe seed of the Avena sativa, LinnĂ©, and the farina derived from the ripened seed (Nat. Ord. Graminaceae). Probably indigenous to Sicily... / ...be about the consistence of milk. Oatmeal gruel, when not otherwise contraindicated, as in diabetes mellitus or amylaceous indigestion, is an excellent and easily digested food in convalescence from e... / ...off the habit has not been sustained. In our own experience we have utterly failed to accomplish any good with it in any form of drug habit. 1

CHIONANTHUS
   The bark of the root of Chionanthus virginicus, LinnĂ©. (Nat. Ord. Oleaceae.) United States from Pennsylvania southward. Dose, 5 to 30... / ...t upon the functions of the pancreas, it is probably of little value in that worst form of diabetes mellitus in which the cells of Langerhans are destroyed. It should be given renewed study in the gly... / ...never reach the true diabetic state. There is good reason to believe that the prolonged use of chionanthus will be of much benefit in such cases.1


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Physician's Materia Medica on Mellitus

GLYCERlN
   A dense fluid remarkable for its strong aflinity for moisture. It is hence of great use as a local depletant, especially to mucous membranes. It is thus applied to the cervix uteri to relieve conges tion and on a similar principle is used in the form of suppositories to cause the bowels to move. In diabetes mellitus, it is sometimes used in place of sugar as a sweetening agent in articles of food.2

JAMBUL
   The seeds of EUGENIA JAMBOLANA, Lam. Astringent, antizymotic; a remedy of great value in some forms of diabetes mellitus, greatly diminishing the excretion of sugar.2


WARNING: All medicines, drugs, plants, chemicals or medicial precedures below are for historical reference only. Many of these treatments are now known to be harmful and possibly fatal. Do not consume any plant, chemical, drug or otherwise without first consulting a licensed physician that practices medine in the appropriate field.

Physician's Therapeutics Memoranda on Mellitus

DIABETES MELLITUS
   Exclude sugar and starch as far as possible from the diet, but do not starve the patient. The remedies most likely to be useful are; Solution Gold and Arsenic Bromide, Fl. Ext. J ambul seed, morphine o_r codeine (particularly Tablets of Codeine without sugar); in gouty cases, colchicine, iodides, lithium salts, and arsenic; in rheumatic cases, salicylic acid, salicylates, potassium iodide. Other remedies are methylene blue (2 to 5 grs. three times a day), uranium nitrate (2 grs. increased gradua...2


References

1) Felter, Harvey Wickes, 1922, The Eclectic Materia Medica, Pharmacology and Therapeutics, Cincinnati, Ohio.
2) Nelson, Baker & Co., 1904, Physician's Handy Book of Materia Medica and Therapeustics, Detroit, Michigan.